When treating HER2-positive invasive breast cancer, doctors often use a combination of drugs to shrink tumors. One common ingredient in these combinations is carboplatin. A large study involving 766 women looked at whether removing this specific drug would change the effectiveness of the treatment or impact patient safety.
The results showed that patients who did not receive carboplatin had nearly identical success rates compared to those who did. Specifically, about 64% of patients in the group without carboplatin achieved a pathologic complete response, while 65.9% of those with it reached the same goal. This means the primary treatment remained highly effective even when one component was removed.
However, there was a significant difference in how well patients tolerated the treatment. Those who did not receive carboplatin experienced much lower rates of severe side effects, such as low white blood cell counts and diarrhea. Serious adverse events were also notably lower in that group. While both treatments worked well to fight the cancer, the version without carboplatin was found to be easier for patients to tolerate.
